Evidence map›Paper›PMID 34754149›Full record

ArticleWorld journal of gastroenterology2021

Importance of

Joaquina Martínez-Galán, Isabel Rodriguez, Octavio Caba

Open access · hybridAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Joaquina Martínez-GalánDepartment of Medical Oncology, Virgen de las Nieves University Hospital, Granada 18014, Spain.
Isabel RodriguezDepartment of Medical Oncology, Virgen de las Nieves University Hospital, Granada 18014, Spain.
Octavio CabaInstitute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada 18016, Spain. ocaba@ugr.es.
Hospital Universitario Virgen de las Nieves · ESUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this editorial, we comment on pancreatic cancer (PC), one of the most aggressive and lethal cancers. Only minimal improvements in survival rates have been achieved over recent years. Available chemotherapeutic regimens have little impact, and surgical resection remains the only reliable curative approach. We address current treatment options for these patients, focusing on the usefulness of

Indexed as

Breast NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsBRCA1 ProteinBRCA2 ProteinFemaleHumansMutationPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCAMaintenanceMutationPancreatic cancerPoly(ADP-ribose) polymerase inhibitorTreatment

Identifiers

PMID34754149
PMCPMC8554401
OpenAlexW3206693792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.